BridgeMD
New treatment option for Knee Osteoarthritis
Official title The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis
ClinicalTrials.gov ID: NCT06574191
What this study is testing
What is Topical Diclofenac gel 1%?
Topical Diclofenac gel 1% is an investigational medicine, given as an once-weekly treatment applied to the skin, being studied as a potential treatment for knee osteoarthritis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to understand the patient and clinic visit characteristics that affect health outcomes for individuals with knee osteoarthritis (OA) pain using topical diclofenac gel. The main questions it aims to answer are: What baseline patient characteristics predict response to topical diclofenac?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- English-speaking
- 50 years of age or older
- Radiographically confirmed knee OA of K/L grade 2 or higher within the past 2 years
- Knee pain at least 15 days/month.
- Average worst daily pain 3/10 or higher over a two-week period.
You likely can't join if
- Medical contraindication to taking NSAIDs such as: history of coronary artery bypass graft, myocardial infarction, coronary artery stent placement...
- Inflammatory arthritis
- Partial or total knee replacement of the index knee
- Recent therapeutic injection of the index knee (less than 12 weeks)
- Planned knee/lower limb surgery during the two-month study period
- Active cancer treatment not in remission or life expectancy less than 6 months
See the full eligibility criteria
- English-speaking
- 50 years of age or older
- Radiographically confirmed knee OA of K/L grade 2 or higher within the past 2 years
- Knee pain at least 15 days/month.
- Average worst daily pain 3/10 or higher over a two-week period.
- Medical contraindication to taking NSAIDs such as: history of coronary artery bypass graft, myocardial infarction, coronary artery stent placement, or stroke within the past 6 months; systolic heart failure with...
- Inflammatory arthritis
- Partial or total knee replacement of the index knee
- Recent therapeutic injection of the index knee (less than 12 weeks)
- Planned knee/lower limb surgery during the two-month study period
- Active cancer treatment not in remission or life expectancy less than 6 months
- Inability to provide informed consent (e.g. dementia)
- Current use of topical or oral NSAIDs more than 3 days per week.
- Inability to receive text messages or emails to complete questionnaires between study visits.
- Unable to follow the study protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Sacramento, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sacramento, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.